Associated Papers
RAS Pathway Mutations and Therapeutics in Vascular Anomalies.
Alharbi S et al.
Pediatric Blood & Cancer, 2025
The Genetic Architecture of Vascular Anomalies: Current Data and Future Therapeutic Perspectives Correlated with Molecular Mechanisms.
Butnariu LI et al.
International Journal of Molecular Sciences, 2022
How we approach genetics in the diagnosis and management of vascular anomalies.
Setty BA et al.
Pediatric Blood & Cancer, 2022
Higher Mutation Burden in High Proliferation Compartments of Heterogeneous Melanoma Tumors.
Grzywa TM et al.
International Journal of Molecular Sciences, 2021
Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.
Pereira TDSF et al.
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2019
A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.
Barclay SF et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2019
30542204 (PubMed )
Supplement: NIHMS1521476-supplement-Supplementary_File.pdf
Etiology and Genetics of Congenital Vascular Lesions.
Queisser A et al.
Otolaryngologic Clinics of North America, 2018
Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma.
Palomba G et al.
Oncology Letters, 2016
Somatic Activating RAS Mutations Cause Vascular Tumors Including Pyogenic Granuloma.
Lim YH et al.
The Journal of Investigative Dermatology, 2015
Select a paper to view details